Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

331 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    China's Medical Device Market: New Policies, Higher Stakes

    The recent introduction of the Regulations on the Supervision and Administration of Medical Devices (also known as State Council Order 650) has created significant impact in the medical device industry in China.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    China's Medical Device Market: New Policies, Higher Stakes

    This paper offers analysis of the major changes, and provides insight into the organizational design and development of the regulatory affairs function at a medical device company in China.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
Ropes & Gray LLP
  • Article

    China Approves World's First Denosumab Biosimilar

    Luye Pharma Group announced last week that China's National Medical Products Administration has approved a marketing launch of BOYOBEI® for treatment of postmenopausal women with osteoporosis at high risk of fractures.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    China's Medical Device Market: Coping With Evolving Regulatory Challenges

    Ask a senior manager of a MedTech company in China what keeps her or him awake at night and "regulatory changes" will invariably be among the first things mentioned.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    APEC Holds High-Level Policy Dialogue On Agricultural Biotechnology

    The Asia-Pacific Economic Cooperation held a High-Level Policy Dialogue on Agricultural Biotechnology in Dalian, China, where participants explored how genome technologies are transforming food production across the region. Experts demonstrated innovations ranging from fish bred with fewer bones to rice varieties designed for diabetic populations, while addressing the critical challenge of public perception and regulatory frameworks. The dialogue emphasized science-based regulation and consumer education as
    ChinaFood, Drugs, Healthcare, Life Sciences
    Bergeson & Campbell
    Bergeson & Campbell
  • Article

    药品技术合同纠纷系列谈(二):违反强制性规定,合同是否无效?

    与药品技术合同定性问题容易引起争议一样,在药品技术合同纠纷中合同效力问题也经常成为案件的争议焦点。
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    China Life Sciences Newsletter - January 2013

    The Fall/Winter 2012 issue of our China Life Sciences Newsletter, a periodic update on key developments, companies, and people in the dynamic China life sciences industry.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Morrison Foerster
    Morrison Foerster
  • Article

    Landmark Whistleblower Program For China's Healthcare Sector

    On October 10, 2024, the National Medical Products Administration in China released the Draft Rule on Rewarding Internal Whistleblowers for Reporting...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    Bipartisan Senate Bill Would Prevent “Offshoring Biotech Industry To Communist China”

    Senators Pete Ricketts and Elissa Slotkin have introduced bipartisan legislation that would subject American investments in adversary biotechnology to federal review requirements. The Biotech Investment National Security Act would amend the COINS Act to include pharmaceutical and biological product development in the list of sectors requiring Treasury Department screening for outbound investments to countries of concern, particularly China.
    ChinaGovernment, Public Sector
    Bergeson & Campbell
    Bergeson & Campbell
  • Article

    China Regulator Fines Two Pharma Firms 320 Million Yuan For Monopolistic Behaviour

    On May 28, China's market regulator said it had fined two pharmaceutical companies 320 million yuan for entering into a monopolistic deal and abusing dominant market position.
    ChinaFood, Drugs, Healthcare, Life Sciences
    AFD China
    AFD China
  • Article

    Chinese Market Biosimilar Update

    This week, Bio-Thera Solutions announced that the China National Medical Products Administration (NMPA) has approved BAT1806, a biosimilar of ACTEMRA (tocilizumab).
    ChinaFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    The "Unofficial" CN Orange Book User Guide For Pharmaceutical Patents

    Toby's Nov 2022 version of "The "Unofficial" CN Orange Book user guide for pharmaceutical patents".
    ChinaIntellectual Property
    Toby Mak
    Toby Mak
  • Article

    "Unofficial" CN Orange Book User Guide For Pharmaceutical Patents (June 2022 Ver.)

    Toby's June 2022 version of "Unofficial" CN Orange Book User Guide Available on IPO Law Journal, and at the link below
    ChinaIntellectual Property
    Toby Mak
    Toby Mak
  • Article

    Biosimilar Approval Updates In Europe And China

    On April 25, 2024, the Committee for Medicinal Products for Human Use ("CHMP") adopted a positive opinion, recommending the granting...
    GlobalFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Global Biosimilar Market Update: Secukinumab Biosimilar Approval In China And Expanded Ustekinumab Licensing Rights

    Bio-Thera Solutions secures NMPA approval for BAT2306, China's first secukinumab biosimilar, while Biocon expands commercialization rights for its ustekinumab biosimilar YESINTEK across nine additional global markets. These developments mark significant milestones in the biosimilar landscape for autoimmune disease treatments.
    GlobalFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    BIOSECURE Update – 1260H List Released

    The Department of Defense has updated its Section 1260H list of Chinese military companies, adding WuXi AppTec and 27 other entities.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Accepts BLA For Shanghai Henlius Biotech's And Organon's HLX14, A Denosumab Biosimilar

    On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab).
    ChinaFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    药品技术合同纠纷系列谈(四):违约责任,如何拿捏?

    根据《合同法》第107条之规定,在药品技术合同的履行过程中,如果一方当事人不履行合同义务或者履行合同义务不符合约定的,另一方当事人&
    ChinaCorporate/Commercial Law
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    China Announces Major Policy Incentives For Life Sciences Companies

    On December 30, 2024, China's State Council published a series of policy incentives in Circular No. 53 to stimulate the transformation of the country's life sciences industry.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    Chinese Medical Device Maker To Pay Swiss Company $3 Mln In Patent Lawsuit

    In the complaint filed by Synthes, three calculation methods were deployed for determining the amount of the damages it claimed.
    ChinaIntellectual Property
    AFD China
    AFD China
  • Showing 1–20 of 331 results

    Next
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics